IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan. 2013

Daisuke Asai, and Toshihiko Imamura, and So-ichi Suenobu, and Akiko Saito, and Daiichiro Hasegawa, and Takao Deguchi, and Yoshiko Hashii, and Kimikazu Matsumoto, and Hirohide Kawasaki, and Hiroki Hori, and Akihiro Iguchi, and Yoshiyuki Kosaka, and Koji Kato, and Keizo Horibe, and Keiko Yumura-Yagi, and Junichi Hara, and Megumi Oda, and
Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.

Genetic alterations of Ikaros family zinc finger protein 1 (IKZF1), point mutations in Janus kinase 2 (JAK2), and overexpression of cytokine receptor-like factor 2 (CRLF2) were recently reported to be associated with poor outcomes in pediatric B-cell precursor (BCP)-ALL. Herein, we conducted genetic analyses of IKZF1 deletion, point mutation of JAK2 exon 16, 17, and 21, CRLF2 expression, the presence of P2RY8-CRLF2 fusion and F232C mutation in CRLF2 in 202 pediatric BCP-ALL patients newly diagnosed and registered in Japan Childhood Leukemia Study ALL02 protocol to find out if alterations in these genes are determinants of poor outcome. All patients showed good response to initial prednisolone (PSL) treatment. Ph⁺, infantile, and Down syndrome-associated ALL were excluded. Deletion of IKZF1 occurred in 19/202 patients (9.4%) and CRLF2 overexpression occurred in 16/107 (15.0%), which are similar to previous reports. Patients with IKZF1 deletion had reduced event-free survival (EFS) and overall survival (OS) compared to those in patients without IKZF1 deletion (5-year EFS, 62.7% vs. 88.8%, 5-year OS, 71.8% vs. 90.2%). Our data also showed significantly inferior 5-year EFS (48.6% vs. 84.7%, log rank P = 0.0003) and 5-year OS (62.3% vs. 85.4%, log rank P = 0.009) in NCI-HR patients (n = 97). JAK2 mutations and P2RY8-CRLF2 fusion were rarely detected. IKZF1 deletion was identified as adverse prognostic factor even in pediatric BCP-ALL in NCI-HR showing good response to PSL.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent

Related Publications

Daisuke Asai, and Toshihiko Imamura, and So-ichi Suenobu, and Akiko Saito, and Daiichiro Hasegawa, and Takao Deguchi, and Yoshiko Hashii, and Kimikazu Matsumoto, and Hirohide Kawasaki, and Hiroki Hori, and Akihiro Iguchi, and Yoshiyuki Kosaka, and Koji Kato, and Keizo Horibe, and Keiko Yumura-Yagi, and Junichi Hara, and Megumi Oda, and
January 2015, Case reports in hematology,
Daisuke Asai, and Toshihiko Imamura, and So-ichi Suenobu, and Akiko Saito, and Daiichiro Hasegawa, and Takao Deguchi, and Yoshiko Hashii, and Kimikazu Matsumoto, and Hirohide Kawasaki, and Hiroki Hori, and Akihiro Iguchi, and Yoshiyuki Kosaka, and Koji Kato, and Keizo Horibe, and Keiko Yumura-Yagi, and Junichi Hara, and Megumi Oda, and
October 2013, Cancer cell international,
Daisuke Asai, and Toshihiko Imamura, and So-ichi Suenobu, and Akiko Saito, and Daiichiro Hasegawa, and Takao Deguchi, and Yoshiko Hashii, and Kimikazu Matsumoto, and Hirohide Kawasaki, and Hiroki Hori, and Akihiro Iguchi, and Yoshiyuki Kosaka, and Koji Kato, and Keizo Horibe, and Keiko Yumura-Yagi, and Junichi Hara, and Megumi Oda, and
July 2019, Blood,
Daisuke Asai, and Toshihiko Imamura, and So-ichi Suenobu, and Akiko Saito, and Daiichiro Hasegawa, and Takao Deguchi, and Yoshiko Hashii, and Kimikazu Matsumoto, and Hirohide Kawasaki, and Hiroki Hori, and Akihiro Iguchi, and Yoshiyuki Kosaka, and Koji Kato, and Keizo Horibe, and Keiko Yumura-Yagi, and Junichi Hara, and Megumi Oda, and
July 2013, International journal of molecular medical science,
Daisuke Asai, and Toshihiko Imamura, and So-ichi Suenobu, and Akiko Saito, and Daiichiro Hasegawa, and Takao Deguchi, and Yoshiko Hashii, and Kimikazu Matsumoto, and Hirohide Kawasaki, and Hiroki Hori, and Akihiro Iguchi, and Yoshiyuki Kosaka, and Koji Kato, and Keizo Horibe, and Keiko Yumura-Yagi, and Junichi Hara, and Megumi Oda, and
April 2018, Haematologica,
Daisuke Asai, and Toshihiko Imamura, and So-ichi Suenobu, and Akiko Saito, and Daiichiro Hasegawa, and Takao Deguchi, and Yoshiko Hashii, and Kimikazu Matsumoto, and Hirohide Kawasaki, and Hiroki Hori, and Akihiro Iguchi, and Yoshiyuki Kosaka, and Koji Kato, and Keizo Horibe, and Keiko Yumura-Yagi, and Junichi Hara, and Megumi Oda, and
May 2015, Genes, chromosomes & cancer,
Daisuke Asai, and Toshihiko Imamura, and So-ichi Suenobu, and Akiko Saito, and Daiichiro Hasegawa, and Takao Deguchi, and Yoshiko Hashii, and Kimikazu Matsumoto, and Hirohide Kawasaki, and Hiroki Hori, and Akihiro Iguchi, and Yoshiyuki Kosaka, and Koji Kato, and Keizo Horibe, and Keiko Yumura-Yagi, and Junichi Hara, and Megumi Oda, and
January 2014, Leukemia,
Daisuke Asai, and Toshihiko Imamura, and So-ichi Suenobu, and Akiko Saito, and Daiichiro Hasegawa, and Takao Deguchi, and Yoshiko Hashii, and Kimikazu Matsumoto, and Hirohide Kawasaki, and Hiroki Hori, and Akihiro Iguchi, and Yoshiyuki Kosaka, and Koji Kato, and Keizo Horibe, and Keiko Yumura-Yagi, and Junichi Hara, and Megumi Oda, and
April 2016, BMC cancer,
Daisuke Asai, and Toshihiko Imamura, and So-ichi Suenobu, and Akiko Saito, and Daiichiro Hasegawa, and Takao Deguchi, and Yoshiko Hashii, and Kimikazu Matsumoto, and Hirohide Kawasaki, and Hiroki Hori, and Akihiro Iguchi, and Yoshiyuki Kosaka, and Koji Kato, and Keizo Horibe, and Keiko Yumura-Yagi, and Junichi Hara, and Megumi Oda, and
June 2023, Lymphatics,
Daisuke Asai, and Toshihiko Imamura, and So-ichi Suenobu, and Akiko Saito, and Daiichiro Hasegawa, and Takao Deguchi, and Yoshiko Hashii, and Kimikazu Matsumoto, and Hirohide Kawasaki, and Hiroki Hori, and Akihiro Iguchi, and Yoshiyuki Kosaka, and Koji Kato, and Keizo Horibe, and Keiko Yumura-Yagi, and Junichi Hara, and Megumi Oda, and
July 2016, Leukemia,
Copied contents to your clipboard!